Predictors of response to tiludronate in Paget's bone disease;Factores que determinan la intensidad de la respuesta al tratamiento con tiludronato en la enfermedad de Paget

Medicina Clinica

Volumn 110, Issue 7, 1998, Pages 254-258

  Morales Piga, A ^a,b   Abraira Santos, V ^b   Rey Rey, José S ^a   De Abajo Iglesias, F ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; TILUDRONIC ACID;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG RESPONSE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MULTIVARIATE ANALYSIS; ORAL DRUG ADMINISTRATION; PAGET BONE DISEASE; PREDICTION;

ADMINISTRATION, ORAL; ADULT; AGED; ALKALINE PHOSPHATASE; DIPHOSPHONATES; ENZYME TESTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; MODELS, THEORETICAL; MULTIVARIATE ANALYSIS; OSTEITIS DEFORMANS; TIME FACTORS;

EID: 0142100173     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. a ed.). Filadelfia: W.B. Saunders, 1990; 546-615.
2. Fleisch H. Experimenta basis for the use of bisphosphonates in Paget's disease of bone. Clin Orthop 1987; 217: 72-78.
3. Mc Intyre I, Evans IMA, Hobitz HHG, Joplin GE, Stevenson JC, Chemistry, physiology, and therapeutic applications of calcitonin. Arthritis Rheum 1980; 23: 1.139-1.147.
4. Harinck HIJ, Papalopoulos SE, Blanksma HJ, Moolenaar AJ, Vermeij P, Bijvoet OLM et al. Paget's disease of bone: early and late responses to three different modes of treatment with aminohydroxipropilidene bisphosphonate (APD). Br Med J 1987; 295: 1.301-1.305.
5. Kanis J, Gray R Long-term follow-up observations on treatment in Paget's disease of bone. Clin Orthop 1987; 217: 99-125.
6. Patel S, Stone M, Coupland C, Hosking D. Determinants of remission of Paget's disease of bone J Bone Miner Res 1993; 8: 1.467-1.473.
7. Bonjour J, Ammann P, Barbier A, Caverzasio J, Rizzoli R. Tiludronate: bone pharmacology and safety. Bone 1995; 17: 473-477.
8. Nagant de Deuxchaisnes C. Devogelaer JP, Cornet F. The effect of the (4-cloro phenil) thiomethylene disodium bisphosphonate or SR 41319B in Paget's disease of bone: a biological study. Srimione: Abstract of the XX European Symposium on Calcified Tissues, 1987.
9. Reginster JY, Jeugmans,Huynen AM, Albert A, Denis D, Deroisy R, Lecart MP et al. Biological and clinical assessment of a new b:sphosphonate (chloro-4 phenyl) thiomethylene bisphosphonate, in the treatment of Paget's disease of bone. Bone 1988; 9: 349-354.
10. Audran M, Clochon P, Etghen D, Mazieres B, Renier JC, Treatment of Paget's disease of bone with (4-chloro-phenyl) thiomethylene bisphosphonate, Clin Rheumatol 1989; 8: 71-79.
11. Reginster JY, Colson F, Morlock B, Combe D, Etghen D, Geusens. P. Evaluation of the efficacy and safety of oral tiludronate in Paget's disease of bone. Arthritis Rheum 1992; 35: 967-974.
12. Mc Clung M, Tou C, Goldstein N, Picot C. Tiludronate therapy for Paget's disease of bone. Bone 1995; 17: 493-496.
13. Charhon S, Meunier P, Ethgen D, Lacheretz F, Breliere J, Roncucci R. Histomorphometric analysis of bone biopies of baboons treated with SR 41319B, a new diphospnonate. Calcif Tissue Int; 1985; 38 (Supl): 33.
14. Geusens P, Nijs J, Van Der Perre G, Van Audekercke R, Lowet G. Goovaerts S et al. Longitudinal effect of tiludronate on bone mineral density, resonant frequency and strength in monkeys. J Bone Min Res 1992; 7: 599-609.
15. Murray RO, Jacobson HG. Miscellaneous disorders of unknown origin. En: Murray RO, editor The radiology of skeletal disorders. Vol. II. Edimburgo: Churchill Livingstone. 1979; 880-881.
16. Coutris G, Analyse des perlurbations des voies principales du metabolisme calcique dans la maladie de Paget. Effets de l'administration du calcitonine. Rev Rhum Mal Osteoartic 1975; 42: 759-767.
17. Fleiss JL. The design and analysis of clinical experiments. Nueva York: John Wiley, 1986.
18. Fels J, Guyonnet J, Berger Y, Cautreels W. Determination of SR41319, a new biphosphonate in biological fluids by HPLC. J Chromat 1988; 430: 73-79.
19. Rowland M, Tozer TN. Clinical pharmacokinetics: concepts and applications Filadelfia: Lea & Febiger, 1980.
20. DA Belsey. Conditioning diagnostic: collinearity and weak data in regression. Nueva York: John Wiley & Sons 1991.
21. Abraira V, Zaplana J, PRESIA: un paquete de procesamientos estadisticos Gijón: Resumenes de la conferencia iberoamericana de bioingenieria, 1984; 100.
22. Abraira V, Pérez de Vargas A, Métodos multivariantes en bioestadistica Madrid: Ed. Centro de estudios Ramon Areces, 1966
23. Harinck HIJ, Bijvoet OL, Blanksma HJ, Dahlinghaus-Nienhuys PJ. Efficacious management with aminobisphosphonate (APD) in Paget's disease of bone. Clin Orthop 1987; 217: 79-97.
24. Siris E, Weinstein R, Altman R, Conte J, Favus M, Lombardi A et al. Comparative study of alendronate versus etidronate for treatment of Paget's bone disease. J Clin Endocrinol Metab 1996; 81: 961-967.
25. Samson E, Necciari J, Thiercelin F. Human pharmacokinetics of Tiludronate. Bone 1995; 479-483.